Latest News for PAVM
NEW YORK, April 9, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April…
PAVmed taps industry veteran Joseph Virgilio to lead its device portfolio relaunch to boost growth, commercialization and long-term shareholder value.
PAVmed (NASDAQ: PAVM - Get Free Report) and Treace Medical Concepts (NASDAQ: TMCI - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability. Risk and Volatility PAVmed has a beta
Medtech industry veteran to oversee development and commercialization of PAVmed's current and future medical device portfolio. Octeris, Inc. subsidiary formed to advance endoscopic esophageal imaging technology recently licensed from Duke University.
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PAVM.
U.S. House Trading
No House trades found for PAVM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.